drugset

Drugs / Lopinavir/Ritonavir

Follow last change Feb 2020 re-read 9 days ago

Lopinavir/Ritonavir

also known as Aluvia (Lopinavir/Ritonavir) · Kaletra · LOP

Developed for: HIV infectious disease
Investigated by: Abbott · University of Toronto · University of Zambia

Trials 1

today NCT01088516 · Ph 4

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT01088516	Dec 2008 → Nov 2011	HIV infectious disease	University of Zambia	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 2

Date	Issuer	Release
2012-03-06	Merck Sharp & Dohme LLC	Results Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗ In this study, concomitant administration of VICTRELIS with ritonavir (Norvir ® ) in combination with atazanavir (Reyataz ® ) or darunavir (Prezista ® ), or with lopinavir/ritonavir (Kaletra ® ) resulted in reduced exposures of the HIV medicines and VICTRELIS.
2012-02-08	Merck Sharp & Dohme LLC	Results Merck Informs U.S. Physicians of Results of Drug Interaction Study of Co-Administration of VICTRELIS™ with Ritonavir-Boosted HIV Protease Inhibitors merck.com ↗ In this study, concomitant administration of VICTRELIS with ritonavir (Norvir®) in combination with atazanavir (Reyataz®) or darunavir (Prezista®),or with lopinavir/ritonavir (Kaletra®) resulted in reduced exposures of the HIV medicines and VICTRELIS.

All press releases naming this drug 5 releases

Date	Issuer	Release
2020-02-27	AbbVie	AbbVie Statement on Coronavirus and lopinavir/ritonavir abbvie.com ↗
2012-03-06	Merck Sharp & Dohme LLC	Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗
2012-02-08	Merck Sharp & Dohme LLC	Merck Informs U.S. Physicians of Results of Drug Interaction Study of Co-Administration of VICTRELIS™ with Ritonavir-Boosted HIV Protease Inhibitors merck.com ↗
2006-08-17	Vertex Pharmaceuticals Incorporated	Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗
2006-05-16	Vertex Pharmaceuticals Incorporated	GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV vrtx.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Lopinavir/Ritonavir	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01088516 ↗
Known as	Aluvia (Lopinavir/Ritonavir)	“Aluvia (Lopinavir/Ritonavir)” NCT01088516 ↗
Known as	Kaletra	“tablet form of LOPINAVIR/RITONAVIR or LOP; established capsule form is known as Kaletra” NCT01088516 ↗
Known as	LOP	“tablet form of LOPINAVIR/RITONAVIR or LOP; established capsule form is known as Kaletra” NCT01088516 ↗
Route	Oral	“Lopinavir/Ritonavir (200/50 mg) two tablets PO BID” NCT01088516 ↗